Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31108144 | 1.00 | HMOX1 (0.57) | HMOX1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31108147 | 1.00 | HMOX1 (0.57) | HMOX1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2538047 | 0.93 | GPR119 (0.53) | HMOX1PIK3CDGPR119 | |
| SCHEMBL29161278 | 0.90 | HMOX1 (0.47) | HMOX1PIK3CDGPR119IDO1TDO2 | |
| SCHEMBL23842628 | 0.88 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL7900769 | 0.86 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL4102372 | 0.86 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL22055497 | 0.86 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL595470 | 0.84 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL595469 | 0.84 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642898-B1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD KK (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | HMOX1 682/4885PIK3CD 2569/4885PIK3CA 2441/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | HMOX1 367/4885PIK3CD 3300/4885PIK3CA 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.